Evidence map›Paper›PMID 25615687›Full record

ArticlePLoS neglected tropical diseases2015

Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line.

Julio Alonso-Padilla, Ignacio Cotillo, Jesús L Presa, Juan Cantizani, Imanol Peña, Ana I Bardera, Jose J Martín, Ana Rodriguez

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. ExploringAntimicrobial agents and chemotherapy · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. The translational challenge in Chagas disease drug development.Memorias do Instituto Oswaldo Cruz · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Identification ofMicroorganisms · 2021
    Article
  17. Anti-International journal of molecular sciences · 2021
    Article
  18. Optimization and biological validation of anBiology methods & protocols · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Julio Alonso-PadillaParasitology Division, Department of Microbiology, New York University School of Medicine, New York, New York, United States of America.
Ignacio CotilloDiseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Jesús L PresaMolecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Juan CantizaniDiseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Imanol PeñaMolecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Ana I BarderaMolecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Jose J MartínMolecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Ana RodriguezParasitology Division, Department of Microbiology, New York University School of Medicine, New York, New York, United States of America.
GlaxoSmithKline (Spain) · ESNew York University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChagas disease, caused by the protozoan parasite Trypanosoma cruzi, represents a very important public health problem in Latin America where it is endemic. Although mostly asymptomatic at its initial stage, after the disease becomes chronic, about a third of the infected patients progress to a potentially fatal outcome due to severe damage of heart and gut tissues. There is an urgent need for new drugs against Chagas disease since there are only two drugs available, benznidazole and nifurtimox, and both show toxic side effects and variable efficacy against the chronic stage of the disease. METHODOLOGY/PRINCIPAL

findingsGenetically engineered parasitic strains are used for high throughput screening (HTS) of large chemical collections in the search for new anti-parasitic compounds. These assays, although successful, are limited to reporter transgenic parasites and do not cover the wide T. cruzi genetic background. With the aim to contribute to the early drug discovery process against Chagas disease we have developed an automated image-based 384-well plate HTS assay for T. cruzi amastigote replication in a rat myoblast host cell line. An image analysis script was designed to inform on three outputs: total number of host cells, ratio of T. cruzi amastigotes per cell and percentage of infected cells, which respectively provides one host cell toxicity and two T. cruzi toxicity readouts. The assay was statistically robust (Z´ values >0.6) and was validated against a series of known anti-trypanosomatid drugs. CONCLUSIONS/SIGNIFICANCE: We have established a highly reproducible, high content HTS assay for screening of chemical compounds against T. cruzi infection of myoblasts that is amenable for use with any T. cruzi strain capable of in vitro infection. Our visual assay informs on both anti-parasitic and host cell toxicity readouts in a single experiment, allowing the direct identification of compounds selectively targeted to the parasite.

Indexed as

AnimalsAutomation, LaboratoryCell LineChlorocebus aethiopsDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysHumansMyoblastsNifurtimoxNitroimidazolesRatsTrypanosoma cruzibenzonidazoleNifurtimoxNitroimidazoles

Identifiers

PMID25615687
PMCPMC4304841
OpenAlexW1964051867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.